Plan your next move right from the start

Edwards SAPIEN platform: The choice for lifetime management

New PARTNER 3 trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year1
  • Time: The only transcatheter heart valve with 90% survival at 5 years6
  • Management: The only transcatheter heart valve with a THV-in-THV indication5*
Visit NEJM to download View the clinical publication

*For patients assessed at high-risk for surgical replacement.

Consistently demonstrating the results you need for the outcomes that matter1

With patients of all ages living longer and having high expectations for their quality of life, lifetime management is increasingly important.2

The first valve choice matters.

From outstanding outcomes and excellent durability* today to facilitating future interventions tomorrow, the SAPIEN platform is designed to deliver a TAVI experience an implanter can count on.3,4

*Propensity matched analysis of intermediate risk patients using VARC-3 definitions of SVD and SVD related BVF at 5 years.

Outcomes

Consistent outcomes that matter, starting with the index procedure.1

Explore outcomes ›

Durability

A comprehensive approach to a durable therapy that offers proven long-term patient outcomes.3

Explore durability ›

Future Interventions

Making future options possible.4,5

Explore future options ›

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVI experience an implanter can count on, starting with the index procedure.

View the brochure

References:

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
2. Life expectancy continued to decrease in 2021 in the EU. Eurostat website. Published May 6, 2022. Accessed August 9, 2023. https://ec.europa.eu/eurostat/en/web/products-eurostat-news/-/ddn-20220506-2.
3. Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in PARTNER-2 trial. J Am Coll Cardiol. 2020;76(16):1830-1843.
4. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972.
5. Tarantini G, et al. Redo-Transcatheter aortic valve implantation using the SAPIEN 3/Ultra transcatheter heart valves – Expert Consensus on Procedural Planning Techniques, The American Journal of Cardiology, 2023.
6. Mack MJ, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N Engl J Med. 2023 Nov 23;389(21):1949-1960.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, PARTNER, PARTNER II and PARTNER 3, are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

PP--EU-6941 v2.0